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Accumulating evidence on the role of Thrombospondin-1 (TSP-1) in the immune
response has emerged during the last years. In spite of the importance of TSP-1 not
only as anti-angiogenic factor but also as an immunomodulatory molecule, studies on
the role of TSP-1 in psoriasis have been neglected. TSP-1 and CD47 expression were
analyzed in skin samples from psoriasis patients and control subjects using RT-PCR and
immunofluorescence. Expression of these molecules was also evaluated in peripheral
blood CD4+ T cells, moDCs, and circulating primary DCs. The functional role of
TSP-1/CD47 signaling axis in psoriasis was assessed in Th17 and Treg differentiation
assays. Additionally, small interfering RNA assays specific to TSP-1 were performed
in CD4+ T cells and monocyte derived DC to specifically evaluate the function of
this protein. Lesional skin of psoriasis patients expressed lower TSP-1 and CD47
mRNA levels compared to non-lesional skin or skin from controls. Immunofluorescence
staining revealed decreased expression of CD47 in CD45+ dermal cells from psoriasis
samples compared to control subjects. Peripheral CD4+ T cells and circulating primary
DCs from psoriasis also expressed lower levels of CD47 compared to controls.
Although no significant differences were detected in TSP-1 expression in CD4+ T cells
and moDCs between patients and controls, TSP-1 expression in psoriasis patients
inversely correlated with disease activity evaluated by the Psoriasis Area and Index
Activity. Furthermore, exogenous TSP-1 inhibited Th17 differentiation and stimulated the
differentiation of CD4+ T cells toward Treg cells. Furthermore, RNA interference specific
for TSP-1 confirmed the role of this molecule as a negative regulator of T cell activation.
Because of the impact of TSP-1/CD47 signaling axis in Th17 and Treg differentiation, a
dysregulated expression of these molecules in the immune cells from psoriasis patients
may favor the exacerbated inflammatory response in this disease.
Keywords: psoriasis, CD47, TSP-1, Th17, Treg cells
Rodríguez-Jiménez et al. TSP-1/CD47 Regulates Th17/Treg Balance in Psoriasis
INTRODUCTION
Psoriasis is considered a chronic inflammatory autoimmune
disease characterized by exacerbated proliferation and disturbed
keratinocyte maturation, inflammatory dermal infiltrates
and changes of the superficial microvasculature that result
in an angiogenic phenotype (1). This condition arises from
interactions between keratinocytes, infiltrating Interleukin
(IL)-17-, IL-22-, and interferon (IFN)-γ-producing cells,
inflammatory macrophages and dendritic cells (DCs) (2).
Clinical investigations and experimental studies indicate that
IFN-γ-producing T helper type (Th)1 cells and CD4+ Th17
cells accompanied by increased expression of IL-17A and
accumulation of CD8+ cytotoxic T cells in psoriatic lesions
cooperate at the interface of innate and adaptive immunity
by activating keratinocytes to produce IL-17C. This cytokine
together with other keratinocyte-derived mediators sustains
chronic inflammation in psoriatic plaques (3–5). Although
inflammation mediated by CD4+ Th17T cells is considered an
important trigger in the development of psoriasis, the precise
underlying immuno-inflammatory mechanisms are still to be
fully defined.
The multicellular protein thrombospondin-1 (TSP-1) is
highly considered for its role in vascular health and disease.
TSP-1 modulates vascular response and at pathologic levels
promotes vascular dysfunction (6, 7). TSP-1 regulates multiple
cellular events involved in tissue repair including cell adhesion,
migration, proliferation, extracellular matrix expression and
organization, and regulation of growth factor activity (8). This
is possible due to its multi-domain structure which interacts
with several cell receptors and matrix proteins (9). Despite
TSP-1 is mostly known for its role in modifying the tumor
micro-environment through its anti-angiogenic properties (10),
growing evidence about the role of TSP-1 in immune response
has emerged in the last decade (11–13).
TSP-1 is known to regulate the conversion of tumor growth
factor β (TGF- β) from latent to an active form (14). On the other
hand, TGF- β1 is a potent keratinocyte growth inhibitor, and its
signaling pathway is downregulated in psoriatic skin leading to
abnormal cell proliferation due to a functional decrease in growth
regulation (15, 16). Independently of TGF- β regulation, TSP-1
may also have suppressive properties by means of its interaction
with CD47 in T cells (17). Particularly, in T CD4+ lymphocytes
TSP-1/CD47 interaction promotes an anti-proliferative effect as
well as the generation of human peripheral regulatory T (Treg)
cells (18–20). Furthermore, when released after the inflammatory
response, the interaction between TSP-1 and CD47 reduces
inflammation linked to T cell activation (20, 21). Interestingly,
methotrexate stimulates the expression of endogenous TSP-1
in primary human T cells, which could explain its beneficial
effects in psoriasis, due to its immunoregulatory effects (22).
Human immature monocyte-derived DCs (moDCs) as well are
known to spontaneously produce TSP-1, this being enhanced
by microbial stimuli (11). It has also been shown that increased
TSP-1 levels during DC activation and its interaction with CD47
and CD36, negatively regulate IL-12, tumor necrosis factor α
(TNF- α) and IL-10 release (23–25). Although our knowledge
about the functional relevance of TSP-1 in psoriasis is scarce,
a defective expression of TSP-1 in keratinocytes from psoriasis
patients correlates with a higher angiogenic response (26). In this
paper, we sought to the role of TSP-1/CD47 signaling axis in the
development and maintenance of psoriatic lesions. Our results
showed that TSP-1 binding to its receptor CD47 was able to
inhibit the differentiation of Th17 cells and favor differentiation
of CD4+ T cells toward Treg cells. Therefore, a diminished
expression of TSP-1 and its receptor CD47 in immune cells from
psoriasis patients may promote the exacerbated inflammatory
response characteristic of this disease.
METHODS
Patients
This study was approved by the Institutional Review Board
(IRB)/Independent Ethics Committee of Hospital de la Princesa
according to the Declaration of Helsinki Principles. After giving
informed consent, 20 healthy individuals and 30 untreated
psoriatic patients were enrolled. Patients were eligible for the
study if they had a Psoriasis Assessment Severity Index (PASI)
≥ 8. The following washout periods were established: 14 days
for topical corticosteroids, 28 days for systemic treatment
including corticosteroids, methotrexate, cyclosporine, acitretin,
or phototherapy and 3 months for biologic agents. From
each psoriasis patient, two non-sun-exposed cutaneous biopsies
(10mm) were taken, one from lesional psoriatic skin and other
from apparently healthy skin (non-lesional skin). At the same
time, 20ml of peripheral venous blood were obtained. Normal
leftover skin samples and peripheral venous blood samples
were obtained from 20 surgical patients. Each biopsy was cut
in half; one piece was snap frozen for RNA isolation and
the other one was embedded in OCTTM compound (Sakura
Finetek, Zoeterwoude, NL) and stored at−80◦C until processing
for immunofluorescence.
Expression of TSP-1 and CD47 mRNA
Levels by RT-PCR
TSP-1 and CD47 mRNA expression levels were determined by
reverse transcription polymerase chain reaction (RT-PCR). Total
RNA was isolated from skin samples, peripheral blood CD4+
T cells and moDCs using TRIzol reagent (Invitrogen) following
the manufacturer’s instructions. One microgram of RNA was
reverse-transcribed to cDNA and amplified with the specific
primers pairs (TSP-1 forward GCC ACA GTT CCT GAT GGA
G, reverse CCA TGG AGA CCA GCC ATC; CD47 forward TCC
ACA GCA CAG CCA AGG T, reverse TCG CAG ATG ACT
TGA GAG TGA AC) using GoTaq qPCR Master Mix (Promega,
WI USA). The data were analyzed using StepOne Plus Software
(Applied Biosystems, Carlsbad, CA). TSP-1 and CD47 mRNA
levels were normalized to GAPDH levels.
Immunofluorescence Staining
Skin OCT sections of 5µm were fixed (formaldehyde 4%),
permeabilized (Triton X-100 0,2%) and blocked with 100µg/ml
human gammaglobulin (Sigma-Aldrich, St. Louis MO, USA) and
a 1:100 dilution of donkey serum (Sigma-Aldrich) in phosphate
Frontiers in Immunology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 1268
Rodríguez-Jiménez et al. TSP-1/CD47 Regulates Th17/Treg Balance in Psoriasis
buffer solution (PBS). Skin sections were then incubated over-
night with 5µg/ml sheep anti-human CD47 (R&D systems, Cat.
AF4670) and mouse anti-human CD45, followed by donkey
anti-sheep (DAS) Alexa Fluor 488 and donkey anti-mouse
(DAM) Alexa Fluor 555. Finally, cell nuclei were counterstained
with DAPI. Negative controls were performed with omission
of the primary antibody. Sections were examined with a
Leica DMR immunofluorescence microscopy under the same
acquisition conditions. Images were analyzed using the ImageJ
sowftware (http://imagej.softonic.com). For the analysis of CD47
expression, fluorescence intensity was determined in regions of
interest (ROIs) drawn on CD45+ cells.
Peripheral Blood CD4+ T Cells and
Monocyte Derived DCs (moDCs)
Peripheral blood mononuclear cells (PBMNCs) were obtained
by density gradient centrifugation and then CD4+ T cells
were isolated by negative selection using magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). For moDCs,
PBMNCs were allowed to adhere for 30min at 37◦C, and
plastic adhered cells were cultured for 5 days in complete media
supplemented with 500 U/ml GM-CSF (Peprotech) and 10 ng/ml
IL-4 (R&D systems). On day 6, 10 ng/ml LPS were added and
after 24 h cells were harvested.
Th17 and Treg Differentiation Assays
For Th17 differentiation, isolated CD4+ T cells were
cultured for 10 days with anti-CD3 (BioLegend Cat# 300314,
RRID:AB314050) plus anti-CD28 mAbs (BD, Cat#555725)
(at 5µg/ml and 2µg/ml, respectively) in the presence of the
combination of cytokines and blocking antibodies appropriate
for polarization: rhIL-6 h IL-1β (10 ng/ml), rhIL-23 (20 ng/ml),
rhTGF-β1 (2 ng/ml), anti-IFN-γ (10µg/ml) and anti-IL-4
(10µg/ml). For Treg polarization, cells were cultured with
TGF-β (5 ng/ml) and IL-2 (20 U/ml) (all cytokines from R&D
systems) for 5 days. Where indicated hTSP-1 (5µg/ml), mouse
anti-human CD47 (1µg/ml) clone B6H12.2 (Abcam Cat#
ab3283, RRID:AB303671) or IgG1 isotype control were also
added. Percentage of IL-17+ and FoxP3+ CD25+ cells (Treg)
was measured in a FACS Canto cytometer and analyzed with
FlowJo software.
siRNA Transfection
Transfections were carried out using 4-D Nucleofector and P3
primary cell kit (Amaxa Lonza, Köln, Germany). Unstimulated
CD4+ T cells or immature moDCs (1 × 106 cells) were
transfected with TSP-1 specific siRNA (50 pmol) selecting
the EO-115 protocol from the 4-D Nucleofector for CD4+
T cells and the protocol CM-120 for moDCs. Immediately
after nucleofection, cells were incubated in X-VIVO 15 (Lonza,
Belgium) medium.
Mixed Leukocytes Reaction (MLR) Assay
CD4+ T cells were co-cultured with moDCs from a different
donor in 96-well U-bottom plates in X-VIVO 15 medium.
The ratio of DCs and CD4+ T cells was 1:5. CD4+ T cells
were preloaded with CellTrace Violet (Invitrogen, by Thermo
Fisher Scientific, OR USA) to follow cell proliferation. Cells were
cultured for 5 days, then intracellular cytokine production and
CellTrace Violet dilution was assessed by flow cytometry.
Treg Suppression Assays
After 5 days of differentiation, Treg cells were isolated using
magnetic beads and added toMLR cultures (ratio 1:2). Responder
CD4+ T cells were from the same donor of Treg cells.
Immediately before the co-culture, responder T cells were loaded
with CellTrace Violet, while Treg cells were loaded with CFSE
(Invitrogen). After 5 days of culture, proliferation of responder
cells was evaluated by flow cytometry.
Statistical Analysis
Data were analyzed with GraphPad Prism (GraphPad Software,
San Diego, CA, USA). One Way Anova, Tukey test and Mann-
Whitney U-test were used as appropriate. Where indicated,
Wilcoxon signed rank test was used to paired data. Data from
T cell differentiation assays were analyzed using Friedman test
and Dunn’s Multiple Comparison. The Spearman test was used
for correlation analysis. Differences were considered significant
at p < 0.05.
RESULTS
Expression of TSP-1 and CD47 was analyzed by RT-PCR in
skin samples from psoriasis patients and healthy controls.
Our data showed that lesional skin from psoriasis patients
express lower levels of TSP-1 and CD47 compared to non-
lesional skin or skin from control subjects (Figures 1A,B).
Immunofluorescence assays showed that CD47 is expressed
in the dermis and epidermis of both control and psoriasis
skin samples. Furthermore, double immunostaining with CD45
identified the expression of CD47 in dermal leukocytes
(Figure 1C). Quantitative analysis demonstrated diminished
levels of CD47 in CD45+ dermal cells of psoriasis patients
compared to cells from non-lesional skin or cells from control
subjects (Figure 1D). Conversely, we did not observe any
difference in the levels of CD47 in keratinocytes between
psoriasis patients and healthy controls (Figure 1E).
Expression of CD47 and TSP-1 was also analyzed in
peripheral blood CD4+ T cells and monocyte-derived DCs
(moDCs). Our data showed that peripheral CD4+ T cells from
psoriasis patients expressed lower levels of CD47 compared
to healthy controls (Figure 2A). Although our results did not
prove significant differences in TSP-1 mRNA levels between
healthy subjects and psoriasis patients (Figure 2A), statistical
analysis showed a negative correlation between TSP-1 expression
and Psoriasis Assessment Severity Index (PASI) (Figure 2B).
However, no correlation between CD47 expression and PASI was
observed (Figure 2B).
The expression of TSP-1 and CD47 was also analyzed in
moDCs under basal conditions or following activation with
LPS. No significant differences were observed in the basal
expression of TSP-1 and CD47 between psoriasis patients
and healthy controls (Figure 2C). However, similarly to our
findings in peripheral CD4+ T cells, TSP-1 expression levels in
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FIGURE 1 | Skin samples from psoriasis patients express lower levels of TSP-1, and CD47 compared with healthy controls. mRNA levels of TSP-1 (A) and its
receptor CD47 (B) were analyzed by RT-PCR in skin samples from 26 psoriasis patients and 20 healthy controls. GAPDH expression was used to normalize gene
expression. Data were analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test, ***p < 0.001, *p < 0.05. (C) Double immunofluorescence staining
of CD47 (green) and CD45 (red) in a representative skin sample from control subjects (left panels) and lesional skin from psoriasis patients (right panels) is shown.
Nuclei were counterstained with DAPI (blue). (D) For quantification of immunofluorescence staining, fluorescence intensity of CD47 in CD45+ dermal cells was
calculated using Image J software. (E) Representative expression of CD47 (green) in skin samples from control subjects and psoriasis patients. Graphs represent
mean ± SD. Differences between groups were determined by one-way ANOVA followed by Tukey’s multiple comparisons test, ****p < 0.0001, **p ≤ 0.001.
immature moDCs negatively correlated with PASI (Figure 2D).
Interestingly, TSP-1 induction in response to LPS was lower
in moDCs from psoriasis patients compared to controls, while
no significant differences in CD47 expression levels were
found (Figure 2E).
CD47 protein levels were evaluated by flow cytometry in
plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) from
psoriasis patients and healthy controls. DCs were identified as
HLA-DR+ Lineage− (CD3, CD14, CD20, CD56) cells and then
selected according to CD123 and CD11c expression (pDCs and
mDCs, respectively) (Figure 3A). Although CD47 protein levels
were high in both pDCs and mDCs, we did not detect any
significant difference in the expression of CD47 between both cell
types (Figure 3B). However, both subsets of circulating DCs from
psoriasis patients expressed significantly lower levels of CD47
compared to cells from healthy subjects (Figures 3B,C).
To evaluate the functional role of CD47 and TSP-1 in
psoriasis inflammatory response we performed Th17 and Treg
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FIGURE 2 | Dysregulated expression of CD47 and TSP-1 in peripheral blood CD4+ T lymphocytes and moDCs. (A,B) CD4+ T cells from psoriasis patients (n = 30)
and healthy controls (n = 18) were isolated from peripheral blood using magnetic microbeads. (A) CD47 and TSP-1 expression was analyzed using real-time PCR.
GAPDH expression was used to normalize data. Differences between groups were analyzed using Mann-Whitney U-test. (B) Correlation between the expression of
CD47 and TSP-1 in CD4+ T cells and PASI determined by Spearman test. (C) Basal expression of CD47 and TSP-1 in non-stimulated moDCS from patients and
controls. Monocytes were isolated from peripheral blood using immune-magnetic bead and differentiated to DCs during 5 days in the presence of IL-4 and GM-CSF.
(D) Correlation between the expression of CD47 and TSP-1 in moDCs cells and PASI determined by Spearman test. (E) Fold induction of CD47 and TSP-1
expression levels in moDCs in response to LPS. moDCs were stimulated for 24 h in the presence of LPS (10 ng/ml), then RNA was isolated and the expression of
TSP-1 and CD47 analyzed by RT-PCR, calculating their fold induction as LPS/basal expression (n = 18). Differences were tested by Mann-Whitney U-test, *p < 0.05.
differentiation assays on peripheral CD4+ T cells from psoriasis
patients and healthy controls. CD4+ T cells were incubated with
the corresponding cocktail of cytokines, and in the presence of
human TSP-1 or anti-CD47mAb that mimics TSP-1 binding (20)
(Figures 4A,B). Our results demonstrated a clear and significant
reduction in the percentage of IL-17+ cells when these cells
were cultured in the presence of TSP-1 or anti-CD47 antibody
(Figures 4A,C) in psoriasis patients (Friedman test p = 0.003).
Similar to our data from psoriasis patients, TSP-1 and anti-
CD47 reduced the percentage of IL-17+ cells in cell cultures
from healthy donors (Friedman test p = 0.007) (Figure 4C).
In addition, we assessed whether TSP-1 or anti-CD47 mAb
were able to affect Treg differentiation. Our results showed that
the addition of TSP-1 induced a significant increment in the
percentage of Treg (CD25+ FoxP3+) cells in samples from
psoriasis patients (Friedman test p = 0.03) (Figures 4B,D).
Although we observed a tendency for anti-CD47 to favor Treg
differentiation, differences were not significant (Figure 4D). In
order to analyze the functionality of CD25+ FoxP3+ cells, we
tested their ability to suppress T cell proliferation. Our data
showed that CD25+ FoxP3+ cells differentiated in the presence
of TSP-1 or anti-CD47 mAb were able to inhibit the proliferation
of T cells in a mixed leukocytes reaction (MLR) (Figure 4E). To
confirm the role of TSP-1 in CD4+ T cell activation, siRNA-
mediated silencing was performed. The levels of exogenously
expressed TSP-1 were monitored by flow cytometry. As shown
in Figure 4F, protein levels dropped in the presence of siRNA
targeted to TSP-1. Both CD25 expression and IFN-γ production
were clearly augmented in T cells transfected with TSP-1-specific
siRNA, when they were activated via TCR (Figure 4F).
Finally, the role of TSP-1/CD47 signaling axis was evaluated
in antigen (Ag) presentation assays with autologous co-cultures
of moDCs with CD4+ T lymphocytes and using the expression
of CD25 as a marker of activation. These assays showed
that the anti-CD47 mAb clearly prevented the activation of
CD4+ T cells during Ag presentation (Figure 5A) in cells
from psoriasis patients. However, the addition of human TSP-
1 had no significant effects on CD25 expression (Figure 5A).
No significant differences were observed in the co-cultures of
cells from control subjects (Figure 5A). These findings contrast
with those observed in T cell differentiation and activation
(Figure 4). The effect of exogenous TSP-1 could be dose
dependent, and it is also important to remark that anti-CD47
(clone B6H12.2) not only mimics TSP-1 binding but blocks
as well the binding of SIRP alpha (27) expressed in DCs.
Thus, to elucidate whether or not TSP-1 expressed by DCs
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FIGURE 3 | Peripheral blood plasmacytoid and myeloid DCs from psoriasis patients express low levels of CD47. (A) Gating strategy for the detection of pDCs and
mDCs. Dendritic cells were identified as HLA-DR positive, Lineage (CD3, CD14, CD20, CD56) negative, CD47 expression was then determined in CD123+ and
CD11c+ by flow cytometry. (B) Representative histograms of CD47 expression in pDCs and mDCs from one patient and one control subject. Red and blues lines
indicates isotype control and CD47 expression, respectively. (C) CD47 expression was calculated as mean fluorescence intensity (MFI) of CD47/MFI isotype control.
Bars represent mean ± SD from 18 psoriasis patients and 10 control subjects. Differences were analyzed by the Mann-Whitney U-test, *p < 0.05.
was playing a role in CD4+ T cell activation, endogenous
expression of TSP-1 was silenced in moDCs by siRNA assays. T
cell activation inMLR assays, evaluated as CD25 expression, IFN-
γ production and proliferation, was augmented in the presence of
moDCs transfected with TSP-1 siRNA (Figure 5B). These data
demonstrate that TSP-1 expressed by moDCs is involved in the
activation of CD4+ T cells.
DISCUSSION
TSP-1/CD47 signaling axis has been considered an important
sensor to maintain homeostasis and regulate innate and adaptive
immune responses (28). In this study we identified a defective
expression of CD47 not only locally in dermal leukocytes, but
also in CD4+ T lymphocytes, pDCs, and mDCs from peripheral
blood. The impact of CD47 deficiency in skin inflammation
has been studied in animal models of contact hypersensitivity
(CHS). An exacerbated T cell-mediated CHS response and
prolonged inflammation indicate the importance of CD47 in
different phases of the inflammatory response (21, 29). Moreover,
a role during disease resolution in CHS has been observed in
TSP-1 deficient mice (21). TSP-1 is present in low amounts in
almost every tissue, but it is rapidly and transiently increased
under stress or in damaged tissues in response to inflammatory
signals (30). In healthy human skin, TSP-1 is produced by
basal epidermal keratinocytes and is deposited in the dermo-
epidermal basement membrane zone, contributing to the barrier
that prevents the growth of blood vessels into the dermis. On
the contrary, TSP-1 expression is downregulated in diseased
skin, such as in skin squamous cell carcinomas (31) and in
keratinocytes from psoriasis patients (26). T cells, macrophages
and DCs may produce and express surface-bound TSP-1 (32–
34). Our present results confirmed that TSP-1 levels are decreased
in the skin of psoriasis patients, although no differences were
detected in the expression of TSP-1 in peripheral CD4+ T
cells or moDCs between patients and controls, However, we
have shown that moDCs from psoriasis patients failed to
upregulate TSP-1 expression in response to LPS. This is in
agreement with the increase of TSP-1 in TLR-activated DCs
vs. immature DCs observed by other authors (11). Thus, TSP-
1 might be considered an important brake in psoriasis and
this could be mediated by its dual effect impairing angiogenesis
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FIGURE 4 | Functional effects of TSP-1 in CD4+ T lymphocytes from psoriasis patients. (A,B) Representative dot plots from Th17 (A) and Treg differentiation (B)
assays in the presence of TSP-1 and anti-CD47 mAb. CD4+ T cells were isolated from peripheral venous blood from psoriasis patients using magnetic beads. Cells (1
× 106/ml) were differentiated to Th17 in the presence or absence of human anti-CD47 mAb 1µg/ml (left) or human TSP-1 5µg/ml (center). (C) Percent of IL- 17+ T
cells from psoriasis patients (n = 13) and control subjects (n = 5) evaluated by flow cytometry after 10 days of culture in the presence of TSP-1, anti-CD47 mAb, or
IgG1 isotype control (1µg/ml). Data were analyzed using Friedman test and Dunn’s multiple comparison test, *p < 0.05. (D) Differentiation of Treg cells in the
presence of anti-CD47 mAb (1µg/ml), TSP-1 (5µg/ml) or IgG1 isotype control (1µg/ml) from psoriasis patients (n = 9) and control subjects (n = 6). Graphs show the
fold induction of FoxP3+ CD25+ cells in the presence of the indicated stimuli compared to the cells cultured only with the differentiation cocktail. (E) Treg suppression
assay, Treg cells differentiated in the presence of TSP-1 or anti-CD47 mAb were isolated by immunomagnetic beads and added to mixed leukocytes reaction (MLR)
cultures. Upper histogram corresponds to control culture (moDCs plus responder T cells), central and lower histograms correspond to MLR cultures plus Treg cells
that were differentiated in the presence of TSP-1 or anti-CD47 mAb (histograms are representative of two independent experiments). (F) Knockdown of TSP-1 favors
T cell activation via TCR. Histogram showing the knockdown efficiency of TSP-1 siRNA. Briefly, unstimulated CD4+ T cells were transfected by nucleofection with
TSP-1 specific or control siRNA (50 pmol), 24 h later T cells were stimulated with anti-CD3/CD28 + IL-2 during 48 h. CD25 expression and IFN-γ production were
evaluated by flow cytometry data. Data correspond to one out of two independent experiments performed by triplicate. Differences were tested by Mann-Whitney
test, *p < 0.05.
in the skin and regulating Th17 and Treg cell differentiation.
Results from in vitro experiments have previously demonstrated
that exogenously added TSP-1 or CD47-binding TSP-1 peptide
inhibit IL-12 secretion by monocytes in response to T cell-
dependent stimuli (35). Moreover, TSP-1 co-stimulates TCR-
activated T cells through its interaction with α4β1 integrin
(17). Our data demonstrate that TSP-1-CD47 interaction or
the incubation with anti-CD47 mAb inhibits the differentiation
of Th17 cells and favors CD4+ T cells differentiation into
Treg cells from psoriasis patients. Topical administration of
a CD47-binding TSP-1 peptide during the development of an
ocular inflammation has been described to attenuate clinical
symptoms of Sjögren syndrome-associated dry eye and augment
FoxP3 expression (36). This is in agreement with previous
results suggesting that TSP-1-mediated activation of TGF-β, as
well as its binding to CD47 may create an anti-inflammatory
environment in certain immune privileged sites such as the eye
(37). It is well-established that CD47/SIRP alpha interaction
negatively regulates antigen presentation (27). The anti-CD47
(clone B6H12.2) used in our functional assays, has been described
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FIGURE 5 | CD47/TSP-1 signaling prevents CD4+ T cell activation in an antigen presentation assay. (A) CD25 expression from CD4+ T cells after antigen
presentation, monocyte-derived DCs from psoriasis patients (n = 8) and healthy controls (n = 3) were cultured for 3 days with autologous peripheral blood CD4+ T
cells in the presence of staphylococcal enterotoxin E. Where indicated, anti-CD47 (1µg/ml), IgG1 isotype control (1µg/ml), or TSP-1 (5µg/ml) were added. Then,
expression of CD25 was evaluated using flow cytometry. Data correspond to mean ± SD and differences were tested using Friedman test, **p < 0.01.
(B) Knockdown of TSP-1 of moDCs augments the activation of T cells following Ag presentation. Histogram showing the knockdown efficiency of TSP-1 siRNA.
Briefly, immature moDCs were transfected by nucleofection with TSP-1 specific or control siRNA (50 pmol), after 48 h moDCs were stimulated with LPS (10 ng/ml)
during 12 h and then co-cultured with heterologous CD4+ T cells. Data correspond to one out of three experiments performed by triplicate. Differences were analyzed
using Mann-Whitney test, *p < 0.05.
to mimic TSP-1 binding but to also block the binding of CD47
with SIRP alpha. We cannot rule out that the blockade of
CD47/SIRP alpha interaction is involved in the effects observed
with anti-CD47 mAb. However, in line to previously published
data this blockade would lead to a higher T cell activation instead
of the inhibition detected in our assays (25, 27, 38). In the case
of effects of exogenous TSP-1, it is difficult to reproduce the
physiological concentration in that particular context. However,
TSP-1 silencing assays clearly show that TSP-1 expressed by DCs
acts as a negative regulator of immune response.
Together these data suggest that TSP-1 and its receptor CD47
may have a role in the exacerbated inflammatory response
characteristic of psoriasis. The link between these molecules and
the angiogenesis and immune regulation raises the possibility
that they could be evaluated as activity markers in psoriasis.
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